CIK 0000886163 · Large accelerated filer
LIGAND PHARMACEUTICALS INC
Sign in to watch- Tickers
- LGND LGNDZ LGNXZ LGNYZ LGNZZ
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770160744
- Phone
- 858-550-7500
- Business address
- 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO, CA, 92121
- Former names
- LIGAND PHARMACEUTICALS
Securities
- LGND Common Stock Nasdaq
- LGNDZ Common stock OTC
- LGNXZ Common stock OTC
- LGNYZ Common stock OTC
- LGNZZ Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $6,585,411
- in 7 filings, $4.5M under 10b5-1 plans
Net −$6,585,411. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-30 | Espinoza Octavio Chief Financial Officer | Other acquisition | +17 | $160.71 | $3K | 27,696 |
| 2026-06-30 | Davis Todd C Chief Executive Officer | Other acquisition | +132 | $160.71 | $21K | 199,513 |
| 2026-06-16 | Sabba Stephen L Director | Option exercise | +2,145 | $66.13 | $142K | 35,774 |
| 2026-06-16 | Sabba Stephen L Director | Sale | −2,145 | $254.00 | $545K | 33,629 |
| 2026-06-16 | Sabba Stephen L Director | Option exercise · Non-Qualified Stock Option (right to buy) | −2,145 | 0 | ||
| 2026-06-12 | Haas Jason Director | Option exercise | +3,000 | $51.56 | $155K | 10,442 |
| 2026-06-12 | Haas Jason Director | Option exercise | +1,000 | $51.56 | $52K | 11,442 |
| 2026-06-12 | Haas Jason Director | Sale | −3,000 | $255.01 | $765K | 8,442 |
| 2026-06-12 | Haas Jason Director | Sale | −3,461 | $256.08 | $886K | 4,981 |
| 2026-06-12 | Haas Jason Director | Option exercise · Non-Qualified Stock Option (right to buy) | −3,000 | 7,138 | ||
| 2026-06-12 | Haas Jason Director | Option exercise · Non-Qualified Stock Option (right to buy) | −1,000 | 6,138 | ||
| 2026-06-11 | Aryeh Jason Director | Sale | −4,500 | $250.00 | $1.1M | 102,580 |
| 2026-06-10 | Aryeh Jason Director | Sale | −500 | $250.00 | $125K | 107,080 |
| 2026-06-10 | LAMATTINA JOHN L Director | Sale | −257 | $247.22 | $64K | 31,303 |
| 2026-06-10 | LAMATTINA JOHN L Director | Sale | −232 | $248.11 | $58K | 31,071 |
| 2026-06-10 | LAMATTINA JOHN L Director | Sale | −697 | $249.53 | $174K | 30,374 |
| 2026-06-10 | LAMATTINA JOHN L Director | Sale | −3,405 | $251.62 | $857K | 26,969 |
| 2026-06-05 | Aryeh Jason Director | Grant or award | +836 | 107,580 | ||
| 2026-06-05 | Aryeh Jason Director | Grant or award · Non-Qualified Stock Option (right to buy) | +2,938 | 2,938 | ||
| 2026-06-05 | Zimmermann Martine Director | Grant or award | +836 | 5,279 |
Page 5 of 43 · 858 trades